Alibaba's health woes show its Midas touch has limits. A unit of the Chinese e-commerce giant has suffered a run-in with mainland regulators. Though shares of the Hong Kong-listed Alibaba Health Information Technology soared when Alibaba took control last year, reality has proved less exciting.
It's a reminder that even boss Jack Ma can't cure investors' loss of faith.
China's food and drug regulator has suspended an electronic drug monitoring system as it overhauls pharmaceutical regulations. That's a big blow for.